Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
IPO Year:
Exchange: NASDAQ
Website: savarapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 5/29/2025 | $2.00 | Buy → Neutral | H.C. Wainwright |
| 12/20/2024 | $8.00 | Overweight | Wells Fargo |
| 11/13/2024 | $7.00 → $5.00 | Outperform → In-line | Evercore ISI |
| 2/15/2024 | $8.00 | Mkt Outperform | JMP Securities |
| 11/7/2023 | $7.00 | Buy | Guggenheim |
| 5/16/2023 | $2.00 → $4.00 | Hold → Buy | Jefferies |
| 3/31/2023 | $2.00 | Buy → Hold | Jefferies |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
10-Q - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
10-Q - Savara Inc (0001160308) (Filer)
DEFA14A - Savara Inc (0001160308) (Filer)
DEF 14A - Savara Inc (0001160308) (Filer)
10-K/A - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
10-K - Savara Inc (0001160308) (Filer)
8-K - Savara Inc (0001160308) (Filer)
Live Leadership Updates
Mr. Parker has More Than 25 Years of Commercial Leadership Experience and has Launched Multiple Rare Disease Products Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the appointment of Braden Parker as Chief Commercial Officer, effective immediately. Mr. Parker is a seasoned global commercial leader with more than 25 years of experience in the healthcare and biotech industry. Throughout his career, he has developed and executed global commercial plans, including market expansion activities, built high-performance teams, and launched multiple successful rare disease products. Mr. Parker is responsible
Pivotal Phase 3 IMPALA-2 Trial Remains On-Track, Top Line Data Expected End of 2Q 2024 IMPALA-2 is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease Received Acceptance from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Revised Pediatric Investigation Plan (PIP) for Molgramostim in aPAP Appoints Raymond Pratt, M.D., Chief Medical Officer Company Ends Quarter with ~$134M, Believes it is Sufficiently Capitalized Through 2025 Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as Chief Medical Officer, effective September 9, 2022. "We appreciate Dr. Chowdhury's contributions during his tenure with the company," said Matt Pauls, Chair and CEO, Savara. "His leadership helped progress our molgramostim nebulizer solution (molgramostim) development program through some important milestones and we wish him well in the future." "I am pleased to have been part of the Savara team and wish the company success in the continued development of molgramostim for the treatment of the rare lung
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright upgraded Savara from Neutral to Buy and set a new price target of $5.00
H.C. Wainwright downgraded Savara from Buy to Neutral and set a new price target of $2.00
Wells Fargo initiated coverage of Savara with a rating of Overweight and set a new price target of $8.00
Evercore ISI downgraded Savara from Outperform to In-line and set a new price target of $5.00 from $7.00 previously
JMP Securities initiated coverage of Savara with a rating of Mkt Outperform and set a new price target of $8.00
Guggenheim initiated coverage of Savara with a rating of Buy and set a new price target of $7.00
Jefferies upgraded Savara from Hold to Buy and set a new price target of $4.00 from $2.00 previously
Jefferies downgraded Savara from Buy to Hold and set a new price target of $2.00
Piper Sandler initiated coverage of Savara with a rating of Overweight and set a new price target of $7.00
Oppenheimer initiated coverage of Savara with a rating of Outperform and set a new price target of $4.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
3 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
4 - Savara Inc (0001160308) (Issuer)
Fastest customizable press release news feed in the world
-- In the Largest Clinical Trial Conducted in Autoimmune PAP, Molgramostim Inhalation Solution (Molgramostim) Reduced Surfactant Burden and Improved Pulmonary Gas Transfer, Respiratory Health-Related Quality of Life, and Patient Functionality -- Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the Phase 3 IMPALA-2 clinical trial will be published online in NEJM. The manuscript, titled "A Phase 3 Trial of Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis" will appear in the August 21, 2025, online version of the publication and can be found at www.nejm.org. Follo
— Savara's Partner, TrilliumBiO, to Present Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP — Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of three abstracts for poster presentation at the European Respiratory Society (ERS) Congress 2025, September 27 – October 1, Amsterdam, The Netherlands. The Company will also host an Industry Evening Mini Symposium titled "Advances in Autoimmune Pulmonary Alveolar Proteinosis" at the meeting. ERS Congress 2025 Posters & Industry Symposium Savara Poster Title: Relationship Between Pulmonary Gas Transfer, R
-- Reached Alignment with the U.S. Food and Drug Administration (FDA) on Information Needed for Resubmission of the Biologics License Application (BLA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- -- Plan to Resubmit the BLA in December with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Will Request Priority Review -- -- Anticipate Submitting the MOLBREEVI Marketing Authorization Applications for Autoimmune PAP to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 1Q 2026 -- -- Reported ~$146M in Cash and Short-Term Investments as of June 30, 2025,
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On July 15, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 20,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 20,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC). The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. Within the next 30 days, the Company intends to request a Type A meeting with the Age
Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 85,000 shares of the Company's common stock and restricted stock units (RSUs) covering an aggregate of 75,000 shares of the Company's common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters Poster Title: Molgramostim Reduces Surfactant Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Phase 3 Clinical Trial Presenter: Tisha S. Wang, M.D
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST. The live webcast and subsequent replay will be available on the "Events & Presentations" section of the Company's corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is
Live finance-specific insights
Statistically Significant Improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) Versus Placebo at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint) Statistically Significant Improvement in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 24 (Secondary Endpoint) 97% of Patients Completed Double-Blind Treatment Through Week 48 with No Trial Drug Related Adverse Events Leading to Discontinuation 100% of Patients Completing the 48-Week Double-Blind Period Elected to Participate in the 96-Week Open-Label Period Company Plans to Complete BLA Submission in 1H 2025 Company to Host Webcast Conference Call Today, Ju
Conference Call to Take Place Tomorrow, Wednesday, June 26, 2024, at 8:00am ET Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30am ET tomorrow, prior to the start of the c
This live feed shows all institutional transactions in real time.
SC 13G - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13D/A - Savara Inc (0001160308) (Subject)
SC 13D/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)
SC 13G/A - Savara Inc (0001160308) (Subject)